Loading clinical trials...

A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943 | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943

A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 Versus Placebo on Calorie Intake and Energy Expenditure in Participants With Obesity Under Calorie Restriction

NCT06313528•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•BMI greater than 30 kg/m2
•History of at least 1 self-reported unsuccessful dietary effort to reduce body weight

Exclusion Criteria

•Change in body weight of greater than 5 kg (11 pounds) within 3 months prior to start of study
•Any of the following treatments for obesity within 1 year prior, or plan to undergo any of these during the study period: liposuction, cryolipolysis, or abdominoplasty
•Prior or planned bariatric or gastric sleeve surgery, endoscopic therapy, or device-based therapy for obesity
•Type 1 or Type 2 Diabetes, history of ketoacidosis, or hyperosmolar state
•Family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome Type 2
•Acute or chronic hepatitis
•Had within 90 days prior: acute myocardial infarction, cerebrovascular accident (stroke), coronary artery revascularization, hospitalization for unstable angina, or hospitalization due to congestive heart failure
•History of active or unstable major depressive disorder or other severe psychiatric disorder within 2 years prior
•History of chronic or acute pancreatitis
•Blood transfusion or severe blood loss within the last 3 months or hemoglobinopathy, hemolytic anemia, sickle cell anemia
+3 more criteria

Locations (3)

AdventHealth Orlando

Orlando, Florida, United States

Pennington Biomedical Research Center

Baton Rouge, Louisiana, United States

Columbia University Irving Medical Center

New York, New York, United States

Key Dates

Start Date

March 20, 2024

Primary Completion Date

August 26, 2025

Completion Date

August 26, 2025

Last Updated

September 23, 2025

Enrollment

ACTUAL participants

Conditions

Obesity

Interventions

LY3437943

DRUG

Placebo

OTHER

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454

Metabolic DiseaseObesity+4 more

View study

RECRUITINGNA

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

NCT07472881

MenopausePerimenopause+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 23, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943

Inclusion Criteria

Exclusion Criteria

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

Protein Supplementation Intervention on Body Weight

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss